IMCR (Immunocore Holdings) Tariff Resilience Score: 6/10 (As of Jul. 09, 2026)


IMCR Immunocore Holdings PLC IMCR
76 GF Score
Price $33.13
GF Value $46.18
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Immunocore Holdings Tariff Resilience Score?

Immunocore Holdings IMCR -2.06% 76 Tariff Resilience Score is 6 as of Jul. 09, 2026. GuruFocus rates IMCR with a GF Score™ of 76/100 and a GF Value™ of $46.18 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,368 Biotechnology companies, Immunocore Holdings ranks better than 75.95% on this metric.

Immunocore Holdings has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Immunocore Holdings has Immunocore's focus on biotech and pharmaceuticals means limited direct tariff exposure, but supply chain dependencies exist. The company can leverage alternative suppliers and has some pricing power. Historical impacts have been minimal.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Immunocore Holdings might have Average Resilient.

Immunocore Holdings  (NAS:IMCR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Immunocore Holdings Tariff Resilience Score Related Terms

IMCR vs MAZE, DMRA, AVBP: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Immunocore Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunocore Holdings Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's Tariff Resilience Score falls into.


IMCR
76GF Score
Immunocore Holdings PLC IMCR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Immunocore Holdings (IMCR) has a Tariff Resilience Score of 6 as of Jul. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Immunocore Holdings ranks #329 out of 1368 companies in the Biotechnology industry, placing it in the top 24%.
Is Immunocore Holdings' Tariff Resilience Score too high?
Immunocore Holdings' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Immunocore Holdings' value of 6 is 50% above this industry median. Based on the distribution chart, Immunocore Holdings ranks #329 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immunocore Holdings has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' Tariff Resilience Score compare to MAZE and DMRA?
According to the Biotechnology industry distribution chart, Immunocore Holdings ranks #329 out of 1368 companies for Tariff Resilience Score. This places Immunocore Holdings in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Immunocore Holdings' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunocore Holdings's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunocore Holdings's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.18, compared to a current price of $33.13 — trading 28.3% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Immunocore Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current Tariff Resilience Score is 6 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunocore Holdings (IMCR) Overvalued in 2026?

Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued. The current stock price of $33.13 is trading 28.3% below its estimated GF Value™ of $46.18. GuruFocus considers Immunocore Holdings to be Modestly Undervalued.

Key valuation signals for IMCR:

  • Tariff Resilience Score: 6
  • GF Value™: $46.18 vs. price of $33.13 (28.3% below fair value)
  • GF Score™: 76/100 with 3 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1368)

No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunocore Holdings Business Description

Other Exchanges 6YG:Germany
Address 92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
76GF Score

Get the complete analysis for IMCR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.13
Price
$46.18
GF Value